peutic interventions currently available or in the foreseeable future [11] . This review will demonstrate the economic consequences of AKI, with the objective to stimulate new prevention and treatment strategies for this common condition.
Cost Estimates in the General AKI Population
Most cost estimates come from single center studies of academic hospitals. Chertow et al. [12] examined costs associated with in-hospital changes in serum creatinine over an 8-month period at Brigham and Women's Hospital. Relative to no AKI, the additional costs attributed to in-hospital AKI ranged from $7,469 for a greater than 25% change in serum creatinine to $33,161 for a greater than 177 µmol/L change in serum creatinine (in 1998 USD). When adjusted for age, sex, admission diagnosis, severity of illness, and CKD, the same definitions of AKI were associated with $3,721 and $22,023 excess hospital costs, respectively. A study at the same academic center conducted 10 years later found similar results [2] . Defining AKI using Kidney Disease Improving Global Outcomes (KDIGO) serum creatinine criteria, AKI was associated with a $7,082 increase in costs. Estimates ranged from $5,400 for KDIGO stage 1 to $27,300 for KDIGO stage 3, with similar multivariable adjustment as Chertow et al. [12] .
Other cost estimates that used serum creatinine criteria to define AKI have been limited to specialized patient populations. In surgical patients at the University of Florida, the risk-adjusted average cost of care for patients undergoing surgery was $26,700 without AKI and $42,600 with any AKI. Patients with RIFLE-R AKI had an additional cost of $10,700, those with RIFLE-I AKI had an additional cost of $21,400, and patients with RIFLE-F AKI had an additional cost of $38,200 compared with patients with no AKI [13] . Similar results were observed in a University of Pittsburgh cohort of cardiac surgery patients. Relative to age-and APACHE III-matched controls, patients with RIFLE-R AKI yielded an additional cost of $11,234, those with RIFLE-I AKI yielded an additional cost of $20,461, and patients with RIFLE-F AKI yielded an additional cost of $34,155 [14] .
A limitation of these studies is that medical care in academic centers tends to be more expensive than the same care in community hospitals [15] . Kerr et al. [16] used routine national data for the National Health Service (NHS) in England to estimate the cost of AKI-related care throughout the entire country. After multiple sensitivity analyses for the prevalence of AKI, the estimated inpatient costs related to AKI ranged from £894,193,943 ($1.4 billion USD) to £1,153,732,733 ($1.8 billion USD), or approximately £1,100 ($1,700 USD) per episode of AKI. This amount was just over 1% of the NHS budget in 2010-2011. Lower estimates outside of academic centers were also found in a study of 23 Massachusetts hospitals, where patients with complicated AKI (AKI requiring mechanical ventilation or an intensive care unit) were excluded [17] . Patients with AKI incurred median direct hospital costs of $2,600, which still exceeded costs for asthma ($1,400), gastrointestinal bleed ($2,100), pneumonia ($2,100), and heart failure ($2,200). Non-academic hospitals incurred 17% lower AKI-related costs compared to academic hospitals.
To determine costs related to AKI in a representative population across the United States, Silver et al. [18] used data from the National Inpatient Sample, which contains administrative data for over 7 million hospitalizations from 95% of the United States population. AKI was associated with an increase in hospitalization costs of $7,933, which decreased to $1,795 when adjusted for patient and hospital characteristics. Compared to other acute medical conditions, adjusted mean increases in the cost of a hospitalization for AKI were similar to hospitalizations for stroke, acute pancreatitis, and pneumonia. Important variation existed in hospital determinants of cost. Nonacademic hospitals incurred 16% lower AKI-related costs compared to academic hospitals, small hospitals incurred 9% lower costs than large hospitals, and the West census region incurred 31% lower costs than the South census region. Similar to the other multicenter studies above, Silver et al. [18] used ICD-9 codes to ascertain AKI, which identify patients with moderate to severe AKI rather than those with mild AKI [19] . Despite not fully accounting for mild AKI, the estimated inpatient costs related to AKI in the United States still ranged from $5.4 to $24.0 billion.
Cost Estimates in Patients with Dialysis-Requiring AKI
The most expensive patients are those with AKI of sufficient severity to require dialysis. Fischer et al. [17] found that dialysis increased costs by 63%, and Silver et al. [18] showed that the additional costs attributed to dialysis-requiring AKI ranged from $11,016 to $42,077. These costs suggest that a small percentage of patients with AKI account for 20-25% of the incremental AKI-related hospital costs. Many of these high cost patients are critically ill. The critical care literature has largely focused on cost differences between intermittent hemodialysis and continuous renal replacement therapy (CRRT), which is approximately a few hundred dollars per day more expensive with CRRT [20, 21] . Regardless of the modality selected, multiple studies have demonstrated that the provision of dialysis in critically ill patients adds between $28,000 and $56,035 with variation related to acute dialysis practice patterns between centers [21] [22] [23] .
More important than modality selection is the costeffectiveness of providing any type of dialysis for critically ill patients. In the SUPPORT study, Hamel et al. [22] followed 490 patients in whom dialysis was initiated. The estimated cost per quality-adjusted life-year (QALY) saved by initiating dialysis and continuing aggressive care rather than withholding dialysis and allowing death to occur was $128,200. Cost-effectiveness varied by estimated survival probability; patients in the worst prognostic category (≤10% survival) had a cost per QALY saved of $274,100, and patients in the best prognostic category (41-60% survival) had a cost per QALY saved of $61,900. Laukkanen et al. [23] added a societal perspective (e.g., long-term disability costs) to their cost-effectiveness analysis in 410 patients with dialysis-requiring AKI. Overall, cost per QALY saved was poor ($271,116). Cost-effectiveness decreased with increasing age, exceeding $750,000 per QALY for patients over 65 years of age. However, cost effectiveness approached the commonly cited threshold of $50,000 per QALY for patients who survived for more than a year and did not require chronic dialysis ($37,172). These results suggest that dialysis in critically ill patients may be cost-effective under certain circumstances, but depends on recovery of kidney function and post-discharge survival, which are difficult outcomes for clinicians to predict a priori. Few studies outside of the intensive care unit have accounted for CKD, ESRD, and other long-term outcomes in their cost analyses. Kerr et al. [16] constructed a Markov model to estimate long-term costs arising from CKD and ESRD in patients who have had AKI relative to a matched group without AKI. They found that post-discharge care for patients with AKI cost the NHS an additional £179 million ($277 million USD) relative to matched controls, but their estimate was very sensitive to small changes in the incidence of long-term (maintenance) dialysis therapy. More research is needed to better quantify the costs associated with post-discharge AKI care.
Conclusions
Several studies now indicate that AKI is expensive and consumes considerable healthcare resources (Table 1) . While it is difficult to fully determine which downstream costs are attributable to AKI rather than a coexisting diagnosis, even the most conservative estimates still attribute approximately $1,700 in excess costs for each episode of AKI and $11,000 in excess costs for each episode of dialysis-requiring AKI. In the United States, at least $5 billion in hospital costs are related to AKI, and the true costs are likely much, much higher. These estimates only account for the inpatient costs of AKI, and ignore AKI that occurs in a primary care setting and the long-term consequences of an AKI episode. Further work is also needed to better understand hospital-level differences in AKI care and patient experiences that influence the decision to initiate renal replacement therapy.
Despite the economic and health consequences of AKI, there have been very few innovations in the prevention and management of AKI over the last decade. In the United Kingdom, a report by the National Confidential Enquiry into Patient Outcome and Death found that 30% of AKI cases were avoidable and only 50% of patients received good care [24] . Small improvements in these numbers could yield substantial cost-savings, which is one of the goals of the NHS Think Kidneys quality improvement program [25] . Similar commitment is required in other jurisdictions to help improve patient outcomes and the patient experience at a reasonable cost for the ever increasing number of patients with AKI.
